Dow Up, Dermata Therapeutics Up

All three major indices rose today.

The NASDAQ rose 203.34 points.

The DOW rose 230.81 points.

The S&P rose 47.62 points.

The Dow Jones Industrial Average closed higher amid rebounding sentiment after the Supreme Court struck down President Donald Trump's sweeping tariffs, easing concerns over potential trade disruptions and boosting risk appetite across equities. The blue-chip index added 230.81 points, or 0.47%, to finish at 49,625.97. This marked a positive session that helped cap a winning week for stocks, with the major indexes recovering from earlier pressures tied to economic data and geopolitical tensions.

All this as Dermata Therapeutics shares rose 0.58 points to end the day at $1.35 per share. The clinical-stage biopharmaceutical company focused on innovative treatments for dermatological diseases stock declined sharply following a period of elevated volatility and extremely high volume the prior day. Trading volume remained elevated at approximately 2,066,300 shares, well above average levels, as the micro-cap biotech continued to digest recent developments including ongoing clinical progress and Nasdaq compliance efforts.

The stock opened at $1.65 and traded in a wide range during the session, hitting a high of $1.75 and a low of $1.30 amid profit-taking after prior gains. The drop represented a 30.05% decrease from the previous close, reflecting typical post-surge consolidation in a highly speculative name with low float and retail-driven momentum.

The performance positioned Dermata Therapeutics among notable movers on a day when broader indices advanced due to positive trade policy news and stabilizing sentiment. Investors continued to monitor the company's pipeline in areas like acne and psoriasis, though the session's pullback highlighted the inherent volatility of small-cap biotech stocks.